2002
DOI: 10.1038/sj.bmt.1703367
|View full text |Cite
|
Sign up to set email alerts
|

Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation?

Abstract: Summary:Relapse at sites of prior disease involvement accounts for the majority of treatment failures following highdose therapy and autologous transplantation for both Hodgkin's disease and non-Hodgkin's lymphoma. Several studies have demonstrated the utility of 'involvedfield' radiation as a treatment modality in this setting to minimize disease bulk prior to transplants, to reduce relapse rates at sites of prior disease involvement and to improve local control for disease resistant to highdose therapy. Othe… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
19
1
2

Year Published

2002
2002
2016
2016

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 24 publications
(22 citation statements)
references
References 35 publications
0
19
1
2
Order By: Relevance
“…2 Although no completed randomised trial has examined the impact of IFRT added to HDT and AuSCT, several retrospective series have indicated improved outcomes with this strategy. [3][4][5][6][7][8][9][10][11] Important concerns regarding the use of IFRT are its potential toxicity and the logistical constraints in integrating radiotherapy with the overall transplant programme.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…2 Although no completed randomised trial has examined the impact of IFRT added to HDT and AuSCT, several retrospective series have indicated improved outcomes with this strategy. [3][4][5][6][7][8][9][10][11] Important concerns regarding the use of IFRT are its potential toxicity and the logistical constraints in integrating radiotherapy with the overall transplant programme.…”
Section: Discussionmentioning
confidence: 99%
“…The potential advantages of post transplant IFRT are the potential to reduce the risks of pneumonitis, veno-occlusive disease (VOD) and gastrointestinal toxicity, no delay in delivering HDT, and the ability to tailor the radiotherapy dose according to the response to the transplant. 2,12 The present study is the first to prospectively evaluate the feasibility and toxicity of a flexible strategy that integrates IFRT at potentially the most favourable time to minimise toxicity -that is, preand/or post transplant, according to the region being irradiated. We have shown this strategy to be feasible in a multicentre setting.…”
Section: Discussionmentioning
confidence: 99%
“…77 It should be noted, however, that similar to much of the data supporting the use of HDCT in the setting of relapsed and refractory HL, the data regarding the use of RT with salvage HDCT is retrospective and often consists of the experience of a single institution. 78 No randomized trials exist and due to the rarity of patients, the age ranges are broad. 77,[79][80][81][82] Most of these studies involve heterogenous populations in terms of indication for RT, dose, timing, and choice of field.…”
Section: Radiation Post-hdctmentioning
confidence: 99%
“…77,[79][80][81][82] Most of these studies involve heterogenous populations in terms of indication for RT, dose, timing, and choice of field. 78 In addition, these data typically do not exclude radiation-naïve subjects. 77,[80][81][82] Data from Emory University from Kahn et al described a cohort in which none had received prior RT.…”
Section: Radiation Post-hdctmentioning
confidence: 99%
See 1 more Smart Citation